Clinical trials for prevention of epileptogenesis

Methods to evaluate treatments that could prevent epileptogenesis in subjects at risk are described. Epilepsy prevention trials are more complex, lengthy, and costly than standard epilepsy treatment trials for many reasons. Issues revolve around selection of subjects, consent for participation, length of follow-up, and selection of an appropriate endpoint. The use of biomarkers are a possible solution in future research.